Ginkgo Bioworks Holdings, Inc.
DNA
$6.79
-$0.45-6.22%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 7.74% | 35.52% | 42.83% | 47.86% | 64.89% |
| Total Depreciation and Amortization | -23.72% | -19.48% | -12.92% | -12.18% | -29.96% |
| Total Amortization of Deferred Charges | 3.89% | -0.53% | 3.89% | 40.60% | -- |
| Total Other Non-Cash Items | -25.94% | -41.28% | -50.96% | -57.86% | -70.66% |
| Change in Net Operating Assets | 70.73% | 50.31% | 54.51% | 69.82% | -373.24% |
| Cash from Operations | 28.38% | 41.02% | 46.47% | 50.50% | 22.07% |
| Capital Expenditure | 87.50% | 96.89% | 87.74% | 59.12% | 12.29% |
| Sale of Property, Plant, and Equipment | -11.42% | -11.42% | -11.42% | -97.18% | -56.86% |
| Cash Acquisitions | -- | -- | -- | 100.00% | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 124.19% | 90.82% | -4,711.39% | -11,730.29% | -44,630.95% |
| Cash from Investing | 119.77% | 92.58% | -286.09% | -263.66% | -221.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 90.40% | 79.51% | 60.54% | 47.43% | 37.95% |
| Issuance of Common Stock | -- | 138,964.29% | 23,077.38% | 10,427.55% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -616.98% | -339.34% | -44.71% | 71.16% | 73.68% |
| Cash from Financing | 3,650.87% | 1,731.52% | 1,122.14% | 534.96% | 51.78% |
| Foreign Exchange rate Adjustments | -195.39% | 96.00% | 171.53% | 364.15% | 157.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 84.87% | 68.65% | -2.48% | -16.51% | -32.31% |